

1 **Correlation between COVID-19 vaccination and inflammatory musculoskeletal**
2 **disorders**

3

4 Young Hwan Park, MD, PhD; Min Ho Kim, PhD; Myeong Geun Choi, MD; Eun Mi Chun,
5 MD, PhD

6

7 **Author Affiliations:** Department of Orthopaedic Surgery, Korea University Guro Hospital,
8 Seoul, Korea (Young Hwan Park); Informatization Department, Ewha Womans University
9 Seoul Hospital, Seoul, Korea (Min Ho Kim); Division of Pulmonary and Critical Care
10 Medicine, Department of Internal Medicine, Mokdong Hospital, Ewha Womans University
11 College of Medicine, Seoul, Korea (Myeong Geun Choi); Division of Pulmonary and Critical
12 Care Medicine, Department of Internal Medicine, Mokdong Hospital, Ewha Womans
13 University College of Medicine, Seoul, Korea (Eun Mi Chun).

14

15 **Author Contributions:** Dr Chun had full access to all of the data in the study and takes
16 responsibility for the integrity of the data and the accuracy of the data analysis. Drs Park and
17 Kim contributed equally as co–first authors.

18 Concept and design: All authors.

19 Acquisition, analysis, or interpretation of data: Park, Kim.

20 Drafting of the manuscript: All authors.

21 Critical revision of the manuscript for important intellectual content: Park, Chun.

22 Statistical analysis: Kim.

23 Obtained funding: None.

24 Administrative, technical, or material support: Park, Chun.

25 Supervision: Chun.

26

27 **Corresponding author:**

28 Eun Mi Chun, MD, PhD, Division of Pulmonary and Critical Care Medicine, Department of

29 Internal Medicine, Mokdong Hospital, Ewha Womans University College of Medicine, 1071

30 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea (cem@ewha.ac.kr).

31

32 **Manuscript word count: 2,317**

33 **Abstract**

34 **Importance:** Earlier research on COVID-19 vaccines identified a range of adverse reactions
35 related to proinflammatory actions that can lead to an excessive immune response and
36 sustained inflammation. However, no study has been conducted on the association between
37 inflammatory musculoskeletal disorders and COVID-19 vaccines.

38 **Objective:** To investigate the incidence rates of inflammatory musculoskeletal disorders
39 following COVID-19 vaccination and to compare them with those of unvaccinated
40 individuals.

41 **Design, Setting, and Participants:** This retrospective nationwide cohort study used data
42 from the Korean National Health Insurance Service (NHIS) database, involving 2,218,715
43 individuals. Data were collected from January 1, 2021, to 12 weeks after the second dose of
44 vaccine for vaccinated individuals and 12 weeks after September 30, 2021, for unvaccinated
45 individuals.

46 **Exposures:** Status was categorized as unvaccinated and vaccinated with mRNA vaccine,
47 viral vector vaccine, and mixing and matching.

48 **Main Outcomes and Measures:** The primary outcome was the occurrence of inflammatory
49 musculoskeletal disorders that were selected as plantar fasciitis (ICD code, M72.2), rotator
50 cuff syndrome (M75.1), adhesive capsulitis (M75.0), herniated intervertebral disc (HIVD)
51 (M50.2/M51.2), spondylosis (M47.9), bursitis (M71.9), Achilles tendinitis (M76.6), and de-
52 Quervain tenosynovitis (M65.4). Multivariate logistic regression analysis was used to
53 determine the risk factors of musculoskeletal disorders after adjusting for potential
54 confounders.

55 **Results:** Among the 2,218,715 individuals, 1,882,640 (84.9%) received two doses of the
56 COVID-19 vaccine, and 336,075 (15.1%) did not. At 12 weeks after vaccination, the
57 incidences of plantar fasciitis (0.14-0.17%), rotator cuff syndrome (0.29-0.42%), adhesive
58 capsulitis (0.29-0.47%), HIVD (0.18-0.23%), spondylosis (0.14-0.23%), bursitis (0.02-
59 0.03%), Achilles tendinitis (0.0-0.05%), and de-Quervain tenosynovitis (0.04-0.05%) were
60 higher in all three vaccinated groups (mRNA, cDNA, and mixing and matching vaccines)
61 when compared to the unvaccinated group. All COVID-19 vaccines were identified as
62 significant risk factors for each inflammatory musculoskeletal disorder (odds ratio, 1.404-
63 3.730), except for mixing and matching vaccines for de-Quervain tenosynovitis.

64 **Conclusions and Relevance:** This cohort study found that individuals who received any
65 COVID-19 vaccine were more likely to be diagnosed with inflammatory musculoskeletal
66 disorders than those who did not. This information will be useful in clarifying the adverse
67 reactions to COVID-19 vaccines and informing people about their potential for inflammatory
68 musculoskeletal disorders after vaccination.

69

70 **Introduction**

71 The COVID-19 pandemic caused by the SARS-CoV-2 virus has had a profound impact on
72 the world, with millions of infections and deaths reported globally. Therefore, extensive
73 efforts were made to develop novel vaccines to combat the virus and curb its spread. The
74 introduction of new COVID-19 vaccines has revolutionized vaccine science, offering
75 unprecedented speed and efficacy during clinical trials.¹ As a result, more than five billion
76 people worldwide have been vaccinated so far, and declarations of public health emergencies
77 have ended in most countries.²

78 Vaccines, inherently designed to stimulate the immune system, have the potential to elicit
79 adverse reactions, which are often linked to immune-mediated responses involving vaccine
80 excipients, active components, or immunodeficiency of the vaccinated individual.^{3,4}
81 Traditional vaccines, with their longstanding accessibility to the public, have been associated
82 with a predictable panel of adverse reactions, most of which are considered harmless.³ The
83 COVID-19 vaccines are no exception to this; therefore, providing clear and transparent
84 information about adverse reactions and demonstrating predictability are essential to
85 increasing public trust and confidence.

86 Early research on COVID-19 vaccines identified a range of adverse reactions related to their
87 proinflammatory effect, which could lead to an excessive immune response and sustained
88 inflammation.⁵ However, other than presenting self-reported symptoms, no studies have been
89 reported on the association of inflammation-related diseases with COVID-19 vaccines,
90 especially in musculoskeletal disorders.⁶⁻⁹ Therefore, this study aimed to investigate the
91 incidence of inflammatory musculoskeletal disorders after COVID-19 vaccination through a
92 large-scale population survey. We used data from the Korean National Health Insurance

93 Service (NHIS) database, which comprises a comprehensive dataset of 2,218,715 individuals.

94

95 **Methods**

96 *Study Design and Population*

97 This nationwide, population-based, retrospective cohort study used data from the Korean
98 NHIS.¹⁰ On January 1, 2021, 50% of the residents of Seoul were randomly selected and
99 included in the study population. The incidence of musculoskeletal disorders among the
100 participants was then analyzed according to their vaccination status. Individuals who received
101 two doses of the COVID-19 vaccine were defined as vaccinated, and their index date was the
102 date of their second vaccination, prior to September 30, 2021. In contrast, the index date for
103 unvaccinated individuals was September 30, 2021. Those who received only one dose of the
104 vaccine and those who started vaccination after September 30, 2021, were excluded from the
105 study. Diagnostic records for 365 d prior to the index date were reviewed, and individuals
106 with any target musculoskeletal disorders as a primary or secondary diagnosis were excluded.
107 If the target musculoskeletal disorder was the primary diagnosis on the day after the index
108 date, it was defined as an event (Figure 1).

109

110 *Data Collection*

111 We accessed the Korean NHIS data, which contains information on all medical claims,
112 including diagnoses. The NHIS data were generated by the accumulation of claims by
113 medical institutions under the Korean health insurance system.¹¹ Data collection was
114 approved by the NHIS and performed in accordance with the NHIS rules on data exploration

115 and utilization.

116 Information on the demographic characteristics of the selected study population, such as age
117 and sex, vaccination status and type, primary and secondary diagnoses from 2020 to 2021,
118 were collected along with dates of hospital visits, underlying disease, and history of COVID-
119 19. Age, sex, insurance level, Charlson comorbidity index (CCI), presence of diabetes,
120 hypertension, hyperlipidemia, and chronic obstructive pulmonary disease (COPD), and
121 history of COVID-19 were retrieved as covariates for the analysis. Regarding vaccination
122 status, the participants were categorized as unvaccinated, messenger ribonucleic acid
123 (mRNA)-vaccinated, viral vector-vaccinated, or mixed and matched. The mRNA vaccines
124 were the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines, while the viral
125 vector vaccines were the Oxford-AstraZeneca (ChAdOx1 nCoV-19) and Johnson & Johnson
126 (Ad26.COV2-S) vaccines. Mixing and matching vaccination was defined as the vaccination
127 method that used heterologous vaccines in the first and second doses.¹² The insurance level
128 was classified as low, middle, and high based on the insurance premiums (medical benefit
129 recipients and grades 1–6 are low, grades 7–13 are middle, and grades 14–20 are high). The
130 CCI, which predicts the 10-year mortality of an individual with a range of comorbid
131 conditions, was calculated based on a previous study by Sundararajan et al.^{13,14} The presence
132 of diabetes, hypertension, hyperlipidemia, and COPD was defined as being registered as a
133 primary or secondary diagnosis more than twice in the year prior to the index date. A history
134 of COVID-19 infection was defined as the presence of the International Classification of
135 Diseases 10th Revision (ICD-10) code U07.1, in either primary or secondary diagnoses
136 before the index date.

137 The target musculoskeletal disorders that were selected to investigate their association with

138 COVID-19 vaccination were musculoskeletal pathological conditions that could be induced,
139 mediated, or aggravated by an inflammatory response. The selection of target
140 musculoskeletal disorders was made through consensus among the authors based on previous
141 studies, and the ICD-10 codes for search were as follows: plantar fasciitis (M72.2),¹⁵ rotator
142 cuff syndrome (M75.1),^{16,17} adhesive capsulitis (M75.0),¹⁸⁻²⁰ herniated intervertebral disc
143 (HIVD) (M50.2/M51.2),²¹⁻²³ spondylosis (M47.9),^{24,25} bursitis (M71.9),²⁶ Achilles tendinitis
144 (M76.6),^{27,28} and de-Quervain tenosynovitis (M65.4).^{29,30}

145

146 *Ethical Approval*

147 This study was approved by the local ethics committee and conducted in accordance with the
148 ethical standards of the Declaration of Helsinki.³¹ The requirement for written informed
149 consent was waived owing to the retrospective nature of the study.

150

151 *Statistical Analysis*

152 The Student's t-test was used to compare continuous variables, and the chi-square test or
153 Fisher's exact test was used to compare categorical variables. Incidence rates were calculated
154 as rates per 100,000 individuals. With demographic characteristics of the study population,
155 including the kind of vaccine received, multivariate logistic regression analysis was
156 performed to determine the risk factors of inflammatory musculoskeletal disorders after
157 adjusting for potential confounders. Associations between these factors and musculoskeletal
158 disorders are summarized as odds ratios (ORs) and 95% confidence intervals (CIs). Statistical
159 significance was set at $p < 0.05$. The SAS Enterprise Guide (SAS Institute, Cary, NC, USA)

160 was used for all statistical analyses and data curation.

161

162 **Results**

163 Among the 2,218,715 individuals in the dataset, 1,882,640 (84.9%) received two doses of the
164 COVID-19 vaccine, while 336,075 (15.1%) did not. The vaccinated group was older,
165 predominantly female, had a higher insurance level, and had more comorbidities compared
166 with the unvaccinated group (Table 1). Within the vaccinated group, the average time interval
167 between the two vaccinations was 50.5 d. For each dose, 1,100,243 (58.4%) individuals
168 received an mRNA vaccine, 656,184 (34.9%) received a viral vector vaccine, and 126,213
169 (6.7%) received a mixing and matching vaccine (Table 2).

170 The incidence of plantar fasciitis, rotator cuff syndrome, adhesive capsulitis, HIVD, and
171 spondylosis was consistently higher in all three vaccination groups (mRNA, cDNA, and
172 mixing and matching vaccines) than in the unvaccinated group. This disparity was evident at
173 2, 4, and 12 weeks after vaccination, with differences in incidence increasing over time
174 (Figures 1-A, 1-B, 1-C, 1-D, and 1-E). For bursitis and Achilles tendinitis, no significant
175 differences in incidence were observed between the three vaccinated groups and the
176 unvaccinated group after 1 and 2 weeks of vaccination. However, at 4 and 12 weeks after
177 vaccination, the incidences of bursitis and Achilles tendinitis were higher in the three
178 vaccinated groups than in the unvaccinated group (Figures 1-F and 1-G). Up to 4 weeks after
179 vaccination, no significant differences in the incidence of de Quervain tenosynovitis were
180 observed; however, at 12 weeks after vaccination, the vaccinated group exhibited a
181 significantly higher incidence than that of the unvaccinated group (Figure 1-H).

182 Multivariate logistic regression analysis showed that 6 weeks after vaccination, the mRNA
183 vaccine, viral vector, and mixing and matching vaccines were significant factors for each
184 musculoskeletal disorder, except for bursitis and de-Quervain tenosynovitis. Over a 12-week
185 period, all vaccines showed statistical significance in relation to each musculoskeletal
186 disorder, except for the mixing and matching vaccines for de-Quervain tenosynovitis (Table
187 3). In addition, female individuals and older individuals were vulnerable to musculoskeletal
188 disorders other than bursitis and Achilles tendinitis after COVID-19 vaccination (Supplement
189 1).

190

191 **Discussion**

192 In this nationwide population-based study, the incidence rates of inflammatory
193 musculoskeletal disorders in terms of adverse reactions after COVID-19 vaccination in Korea
194 were investigated. We found that initially after vaccination, the incidences of plantar fasciitis,
195 rotator cuff syndrome, adhesive capsulitis, HIVD, and spondylosis, which are inflammation-
196 related disorders involving tendons and connective tissues, were higher in the vaccinated
197 group than in the unvaccinated group, regardless of the type of vaccine received. At 12 weeks
198 after vaccination, all inflammatory musculoskeletal disorders investigated, including bursitis,
199 Achilles tendinitis, and de Quervain tenosynovitis, showed a higher incidence in the
200 vaccinated group than in the unvaccinated group. These findings provide detailed information
201 on the adverse reactions after COVID-19 vaccination, especially in terms of inflammation-
202 related musculoskeletal disorders. We believe that this information will be beneficial for
203 establishing the predictability of adverse reactions and enhancing public understanding of
204 COVID-19 vaccination.

205 Inflammatory musculoskeletal manifestations after COVID-19 vaccination have been
206 repeatedly reported in case reports and small cohort studies.³² In one of the largest case
207 studies conducted, Ursini et al. concluded that inflammatory musculoskeletal disorders may
208 occasionally develop in close temporal association with COVID-19 vaccination.³³ Along with
209 these previous studies, our study highlights the development of inflammatory
210 musculoskeletal disorders after COVID-19 vaccination. However, an association between
211 COVID-19 vaccines and inflammatory musculoskeletal disorders is yet to be established.
212 According to the hypothetical mechanisms of autoimmune phenomena after COVID-19
213 vaccination, either adjuvants or the vaccine itself may induce an overactive immune reaction,
214 autoimmune consequences, or even inflammation in susceptible individuals.³⁴ As a form of
215 molecular mimicry, a hypothesis states that overwhelming systemic or local inflammation is
216 activated by the cross-reaction of the immune response between antigens in vaccines and
217 molecular structures *in vivo*.³⁵ The series of inflammatory musculoskeletal disorders that
218 showed a strong correlation with COVID-19 vaccinations in this study are expected to be
219 included in the list of adverse reactions to COVID-19 vaccines. Therefore, future studies are
220 needed to identify the mechanisms that link COVID-19 vaccines to inflammatory
221 musculoskeletal disorders and prevent or mitigate these adverse reactions.

222 Regarding the inflammatory musculoskeletal disorders investigated in this study, the
223 incidence rates of shoulder-related disorders, such as rotator cuff syndrome and adhesive
224 capsulitis, were notably higher than those of other disorders—nearly doubling the rate of
225 other disorders. We believe that shoulder injury related to vaccine administration (SIRVA),³⁶
226 which has already been reported for existing vaccines, may have contributed to the high
227 incidence rates observed. SIRVA is thought to occur by provoking an inflammatory reaction

228 when vaccines are injected through the deltoid into underlying non-muscular tissues.³⁷
229 Subsequent prolonged inflammatory responses after SIRVA could progress to bursitis,
230 tendinitis, and capsulitis around the shoulder joint.³⁸ The findings of this study indicate that
231 the COVID-19 vaccine is not exempt from SIRVA. Therefore, as with other vaccination
232 procedures, we emphasize increased attention to the injection site during the administration
233 of the COVID-19 vaccine.

234 Previous studies on adverse reactions to the COVID-19 vaccine showed that most systemic
235 adverse reactions were more frequent in female individuals than in male individuals and in
236 younger age groups than in older age groups.^{6,7} In our study, the incidence rates of
237 inflammatory musculoskeletal disorders, regarded as adverse effects, were higher in females,
238 which is consistent with the reports of previous studies. However, in terms of age, older
239 individuals had a higher incidence of inflammatory musculoskeletal disorders compared to
240 younger individuals. Two possible explanations exist for the inconsistency between our age-
241 specific findings and those of previous reports. First, older individuals exhibit a reduced
242 capacity to mount an effective response to vaccines as well as a lower frequency of
243 neutralizing antibodies compared to younger populations.^{39,40} Moreover, older patients may
244 be more prone to progressing from mild adverse reactions to inflammation-related
245 musculoskeletal disorders compared to their younger counterparts. Similarly, although the
246 overall incidence of adverse reactions after COVID-19 vaccination was higher in the younger
247 age group, the incidence of severe adverse reactions was reported to be higher in the older
248 age group.⁴¹ Second, as with other adverse reactions, inflammatory musculoskeletal disorders
249 occurred more frequently in the younger than in the older age group; however, in the dataset,
250 diagnosis and insurance claims appeared to occur more frequently in older individuals

251 because younger patients visited medical institutions less often. Irrespective of which of these
252 two possibilities is true, we maintain that the need for attention after vaccination in older
253 individuals remains unchanged.

254

255 *Strengths and Limitations*

256 The strength of our study is underscored by its substantial sample size, which comprises data
257 from over 2 million individuals randomly selected from the Korean NHIS. This
258 comprehensive database, which encompasses medical services for 97% of the population,
259 enhances the reliability and representativeness of our findings.¹⁰ Such large population-based
260 databases, which are available only in Taiwan, Sweden, and Korea, are excellent resources
261 for answering questions that are difficult to address using single-institution or small-scale
262 studies.⁴²

263 Our study also has several limitations. First, because the target musculoskeletal disorders
264 were identified by ICD-10 codes in the claims database, coding, mismatching, or
265 misclassification errors could have occurred. Discrepancies might have occurred between the
266 actual disease and the diagnosis claimed by the healthcare provider, and over- or
267 underdiagnosis may occur. Second, our study could not confirm the pathophysiological
268 mechanism of the change in the incidence of musculoskeletal disorders after COVID-19
269 vaccination because it relied only on diagnoses claimed by healthcare providers. As COVID-
270 19 vaccines are frequently accompanied by arthralgia and myalgia,^{6,7} whether these adverse
271 reactions were misdiagnosed as inflammation-mediated musculoskeletal disorders or whether
272 the pain was caused by an actual inflammatory disorder is unknown. Further studies
273 involving laboratory data and inflammatory biomarkers are required to address these

274 limitations.

275

276 **Conclusions**

277 Individuals who received COVID-19 vaccines, either mRNA, viral vector, or mixing and
278 matching, were found to be more likely to be diagnosed with inflammatory musculoskeletal
279 disorders compared to those who did not. Our results provide detailed information on the
280 adverse reactions after COVID-19 vaccination, with a particular focus on inflammatory
281 musculoskeletal disorders. This information will be useful in clarifying adverse reactions to
282 COVID-19 vaccines and educating people about the potential risk of inflammatory
283 musculoskeletal disorders based on their vaccination status.

284

285 **Acknowledgment:** None

286 **Conflict of Interest Disclosures:** None

287 **Funding/Support:** None

288 **Data availability:** See Appendix 1.

289

290 **References**

- 291 **1.** Ball P. The lightning-fast quest for COVID vaccines – and what it means for other diseases.
292 *Nature*. 2021;589(7840):16-18. doi: [10.1038/d41586-020-03626-1](https://doi.org/10.1038/d41586-020-03626-1).
- 293 **2.** Our world in data. Coronavirus (COVID-19) vaccinations.
294 <https://ourworldindata.org/covid-vaccinations>.
- 295 **3.** Stone CA Jr, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse
296 reactions to vaccines. *Br J Clin Pharmacol*. 2019;85(12):2694-2706. doi: [10.1111/bcp.14112](https://doi.org/10.1111/bcp.14112).
- 297 **4.** Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ,
298 Narasimhan B. Vaccine adjuvants: current challenges and future approaches. *J Pharm Sci*.
299 2009;98(4):1278-1316. doi: [10.1002/jps.21523](https://doi.org/10.1002/jps.21523).
- 300 **5.** Lamprinou M, Sachinidis A, Stamoula E, Vavilis T, Papazisis G. COVID-19 vaccines
301 adverse events: potential molecular mechanisms. *Immunol Res*. 2023;71(3):356-372. doi:
302 [10.1007/s12026-023-09357-5](https://doi.org/10.1007/s12026-023-09357-5).
- 303 **6.** Kitagawa H, Kaiki Y, Sugiyama A, et al. Adverse reactions to the BNT162b2 and mRNA-
304 1273 mRNA COVID-19 vaccines in Japan. *J Infect Chemother*. 2022;28(4):576-581. doi:
305 [10.1016/j.jiac.2021.12.034](https://doi.org/10.1016/j.jiac.2021.12.034).
- 306 **7.** Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after
307 vaccination in users of the COVID Symptom Study app in the UK: a prospective
308 observational study. *Lancet Infect Dis*. 2021;21(7):939-949. doi: [10.1016/S1473-](https://doi.org/10.1016/S1473-3099(21)00224-3)
309 [3099\(21\)00224-3](https://doi.org/10.1016/S1473-3099(21)00224-3).
- 310 **8.** Sharma A, Parekh SG. Musculoskeletal sequelae following COVID-19 mRNA vaccination:
311 a Case Report. *J Orthop Rep*. 2022;1(3):100044. doi: [10.1016/j.jorep.2022.100044](https://doi.org/10.1016/j.jorep.2022.100044).
- 312 **9.** Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and

- 313 reactogenicity of COVID-19 vaccines: A vaccine recipient survey. *Life (Basel)*. 2021;11(3).
314 doi: [10.3390/life11030249](https://doi.org/10.3390/life11030249).
- 315 **10.** Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance
316 Service-National sample cohort (NHIS-NSC), South Korea. *Int J Epidemiol*. 2017;46(2):e15.
317 doi: [10.1093/ije/dyv319](https://doi.org/10.1093/ije/dyv319).
- 318 **11.** Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National
319 Health Insurance Service (NHIS) and health insurance review y assessment (HIRA) database
320 for research. *J Lipid Atheroscler*. 2022;11(2):103-110. doi: [10.12997/jla.2022.11.2.103](https://doi.org/10.12997/jla.2022.11.2.103).
- 321 **12.** Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-
322 and-match: the concept, the efficacy and the doubts. *J Med Virol*. 2022;94(4):1294-1299. doi:
323 [10.1002/jmv.27463](https://doi.org/10.1002/jmv.27463).
- 324 **13.** Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10
325 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol*.
326 2004;57(12):1288-1294. doi: [10.1016/j.jclinepi.2004.03.012](https://doi.org/10.1016/j.jclinepi.2004.03.012).
- 327 **14.** Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
328 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*.
329 1987;40(5):373-383. doi: [10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8).
- 330 **15.** Rabadi D, Seo S, Wong B, Chung D, Rai V, Agrawal DK. Immunopathogenesis, early
331 Detection, current therapies and prevention of plantar fasciitis: A concise review. *Int*
332 *Immunopharmacol*. 2022;110:109023. doi: [10.1016/j.intimp.2022.109023](https://doi.org/10.1016/j.intimp.2022.109023).
- 333 **16.** Voloshin I, Gelinis J, Maloney MD, O'Keefe RJ, Bigliani LU, Blaine TA.
334 Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in
335 patients with rotator cuff disease. *Arthroscopy*. 2005;21(9):1076.e1-1076.e9. doi:
336 [10.1016/j.arthro.2005.05.017](https://doi.org/10.1016/j.arthro.2005.05.017).

- 337 **17.** Nho SJ, Yadav H, Shindle MK, Macgillivray JD. Rotator cuff degeneration: etiology and
338 pathogenesis. *Am J Sports Med.* 2008;36(5):987-993. doi: [10.1177/0363546508317344](https://doi.org/10.1177/0363546508317344).
- 339 **18.** Dakin SG, Rangan A, Martinez F, et al. Tissue inflammation signatures point towards
340 resolution in adhesive capsulitis. *Rheumatol (Oxf Engl).* 2019;58(6):1109-1111. doi:
341 [10.1093/rheumatology/kez007](https://doi.org/10.1093/rheumatology/kez007).
- 342 **19.** Neviasser AS, Neviasser RJ. Adhesive capsulitis of the shoulder. *J Am Acad Orthop Surg.*
343 2011;19(9):536-542. doi: [10.5435/00124635-201109000-00004](https://doi.org/10.5435/00124635-201109000-00004).
- 344 **20.** Lho YM, Ha E, Cho CH, et al. Inflammatory cytokines are overexpressed in the
345 subacromial bursa of frozen shoulder. *J Shoulder Elbow Surg.* 2013;22(5):666-672. doi:
346 [10.1016/j.jse.2012.06.014](https://doi.org/10.1016/j.jse.2012.06.014).
- 347 **21.** Hsu YH, Lin RM, Chiu YS, Liu WL, Huang KY. Effects of IL-1beta, IL-20, and BMP-2
348 on intervertebral disc inflammation under hypoxia. *J Clin Med.* 2020;9(1). doi:
349 [10.3390/jcm9010140](https://doi.org/10.3390/jcm9010140).
- 350 **22.** Kawaguchi S, Yamashita T, Yokogushi K, Murakami T, Ohwada O, Sato N.
351 Immunophenotypic analysis of the inflammatory infiltrates in herniated intervertebral discs.
352 *Spine (Phila Pa 1976).* 2001;26(11):1209-1214. doi: [10.1097/00007632-200106010-00008](https://doi.org/10.1097/00007632-200106010-00008).
- 353 **23.** Molinos M, Almeida CR, Caldeira J, Cunha C, Gonçalves RM, Barbosa MA.
354 Inflammation in intervertebral disc degeneration and regeneration. *J R Soc Interface.*
355 2015;12(108):20150429. doi: [10.1098/rsif.2015.0429](https://doi.org/10.1098/rsif.2015.0429).
- 356 **24.** Yin J, Huang Y, Gao G, Nong L, Xu N, Zhou D. Changes and significance of
357 inflammatory cytokines in a rat model of cervical spondylosis. *Exp Ther Med.*
358 2018;15(1):400-406. doi: [10.3892/etm.2017.5418](https://doi.org/10.3892/etm.2017.5418).
- 359 **25.** Emery SE. Cervical spondylotic myelopathy: diagnosis and treatment. *J Am Acad Orthop*
360 *Surg.* 2001;9(6):376-388. doi: [10.5435/00124635-200111000-00003](https://doi.org/10.5435/00124635-200111000-00003).

- 361 **26.** Aaron DL, Patel A, Kayiaros S, Calfee R. Four common types of bursitis: diagnosis and
362 management. *J Am Acad Orthop Surg*. 2011;19(6):359-367. doi: [10.5435/00124635-](https://doi.org/10.5435/00124635-201106000-00006)
363 [201106000-00006](https://doi.org/10.5435/00124635-201106000-00006).
- 364 **27.** Legerlotz K, Jones ER, Screen HR, Riley GP. Increased expression of IL-6 family
365 members in tendon pathology. *Rheumatol (Oxf Engl)*. 2012;51(7):1161-1165. doi:
366 [10.1093/rheumatology/kes002](https://doi.org/10.1093/rheumatology/kes002).
- 367 **28.** D'Addona A, Maffulli N, Formisano S, Rosa D. Inflammation in tendinopathy. *Surgeon*.
368 2017;15(5):297-302. doi: [10.1016/j.surge.2017.04.004](https://doi.org/10.1016/j.surge.2017.04.004).
- 369 **29.** Kuo YL, Hsu CC, Kuo LC, et al. Inflammation is present in de Quervain disease—
370 correlation study between biochemical and histopathological evaluation. *Ann Plast Surg*.
371 2015;74(suppl 2):S146-S151. doi: [10.1097/SAP.0000000000000459](https://doi.org/10.1097/SAP.0000000000000459).
- 372 **30.** Clarke MT, Lyall HA, Grant JW, Matthewson MH. The histopathology of de Quervain's
373 disease. *J Hand Surg Br*. 1998;23(6):732-734. doi: [10.1016/s0266-7681\(98\)80085-5](https://doi.org/10.1016/s0266-7681(98)80085-5).
- 374 **31.** World Medical Association. World Medical Association Declaration of Helsinki: ethical
375 principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194.
376 doi: [10.1001/jama.2013.281053](https://doi.org/10.1001/jama.2013.281053).
- 377 **32.** Chen CC, Chen CJ. New-onset inflammatory arthritis after COVID-19 vaccination: A
378 systematic review. *Int J Rheum Dis*. 2023;26(2):267-277. doi: [10.1111/1756-185X.14482](https://doi.org/10.1111/1756-185X.14482).
- 379 **33.** Ursini F, Ruscitti P, Raimondo V, et al. Spectrum of short-term inflammatory
380 musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases.
381 *Ann Rheum Dis*. 2022;81(3):440-441. doi: [10.1136/annrheumdis-2021-221587](https://doi.org/10.1136/annrheumdis-2021-221587).
- 382 **34.** Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19
383 vaccination. *Immunology*. 2022;165(4):386-401. doi: [10.1111/imm.13443](https://doi.org/10.1111/imm.13443).
- 384 **35.** Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and

- 385 immune crossreaction. *Cell Mol Immunol*. 2018;15(6):586-594. doi: [10.1038/cmi.2017.151](https://doi.org/10.1038/cmi.2017.151).
- 386 **36.** Wiesel BB, Keeling LE. Shoulder injury related to vaccine administration. *J Am Acad*
387 *Orthop Surg*. 2021;29(17):732-739. doi: [10.5435/JAAOS-D-21-00021](https://doi.org/10.5435/JAAOS-D-21-00021).
- 388 **37.** Atanasoff S, Ryan T, Lightfoot R, Johann-Liang R. Shoulder injury related to vaccine
389 administration (SIRVA). *Vaccine*. 2010;28(51):8049-8052. doi:
390 [10.1016/j.vaccine.2010.10.005](https://doi.org/10.1016/j.vaccine.2010.10.005).
- 391 **38.** Bodor M, Montalvo E. Vaccination-related shoulder dysfunction. *Vaccine*.
392 2007;25(4):585-587. doi: [10.1016/j.vaccine.2006.08.034](https://doi.org/10.1016/j.vaccine.2006.08.034).
- 393 **39.** Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine
394 responses. *J Allergy Clin Immunol*. 2020;145(5):1309-1321. doi: [10.1016/j.jaci.2020.03.017](https://doi.org/10.1016/j.jaci.2020.03.017).
- 395 **40.** Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the
396 Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. *Clin Infect Dis*.
397 2021;73(11):2065-2072. doi: [10.1093/cid/ciab381](https://doi.org/10.1093/cid/ciab381).
- 398 **41.** Xiong X, Yuan J, Li M, Jiang B, Lu ZK. Age and gender disparities in adverse events
399 following COVID-19 vaccination: real-world evidence based on big data for risk
400 management. *Front Med (Lausanne)*. 2021;8:700014. doi: [10.3389/fmed.2021.700014](https://doi.org/10.3389/fmed.2021.700014).
- 401 **42.** Shin DW, Cho B, Guallar E. Korean national health insurance database. *JAMA Intern*
402 *Med*. 2016;176(1):138. doi: [10.1001/jamainternmed.2015.7110](https://doi.org/10.1001/jamainternmed.2015.7110).

403

404

405 **Table 1.** Demographic characteristics of the study population

	Total	Vaccinated	Unvaccinated	p value
Sex				
Male	1,017,422 (45.9)	862,251 (45.8)	155,171 (46.2)	<0.001
Female	1,201,293 (54.1)	1,020,389 (54.2)	180,904 (53.8)	
Age				
Mean ± SD, years	54.1 ± 17.3	45.3 ± 17.2	55.7 ± 16.8	<0.001
20–29	264,779 (11.9)	201,896 (10.7)	62,883 (18.7)	<0.001
30–39	241,993 (10.9)	155,240 (8.3)	86,752 (25.8)	
40–49	282,150 (12.7)	211,572 (11.2)	70,578 (21.0)	
50–59	508,893 (22.9)	461,880 (24.5)	47,016 (14.0)	
60–39	502,417 (22.7)	468,525 (24.9)	33,892 (10.1)	
70–79	276,783 (12.5)	259,784 (13.8)	16,999 (5.1)	
≥80	141,700 (6.4)	123,743 (6.6)	17,957 (5.3)	
Insurance level				
Low	570,560 (25.7)	472,383 (25.1)	98,177 (29.2)	<0.001
Middle	611,733 (27.6)	506,536 (26.9)	105,197 (31.3)	
High	1,036,422 (46.7)	903,721 (48.0)	132,701 (39.5)	
Comorbidity				

Diabetes mellitus	351,517 (15.8)	329,043 (17.5)	22,474 (6.7)	<0.001
Hyperlipidemia	708,007 (31.9)	666,137 (35.4)	41,870 (12.5)	<0.001
Hypertension	624,705 (28.2)	587,304 (31.2)	37,398 (11.1)	<0.001
COPD	93,785 (4.2)	85,634 (4.6)	8,151 (2.4)	<0.001
COVID-19 history	18,411 (0.8)	14,511 (0.8)	3,900 (1.2)	<0.001
CCI				
0	1,473,982 (66.4)	1,194,333 (63.4)	279,649 (83.2)	<0.001
1	372,684 (16.8)	346,869 (18.4)	25,815 (7.7)	
≥2	372,049 (16.8)	341,438 (18.2)	30,611 (9.1)	

406 Data are n (%), unless otherwise indicated.

407 SD, standard deviation; COPD, Chronic obstructive pulmonary disease; CCI, Charlson Comorbidity Index.

408

409

410

411

412

413 **Table 2.** Summary of the first and second doses of the COVID-19 vaccines received

First dose	Second dose	Number (%)
Pfizer-BioNTech ^a	Pfizer-BioNTech	1,072,100 (56.9)
	Moderna	21 (0.0)
	Oxford-AstraZeneca	4 (0.0)
	Johnson & Johnson	2 (0.0)
Oxford-AstraZeneca ^b	Oxford-AstraZeneca	656,184 (34.8)
	Pfizer-BioNTech	126,196 (6.7)
	Johnson & Johnson	6 (0.0)
	Moderna	2 (0.0)
Moderna ^a	Moderna	28,110 (1.5)
	Pfizer-BioNTech	5 (0.0)
Johnson & Johnson ^b	Oxford-AstraZeneca	5 (0.0)
	Pfizer-BioNTech	5 (0.0)

414 ^a mRNA vaccine

415 ^b Viral vector vaccine

416

417

418

419

420

421

422

423

424 **Table 3.** Results of multivariate logistic regression model to assess the risk of musculoskeletal disorders after COVID-19 vaccination.

Variable	1 week			2 weeks			4 weeks			12 weeks			
	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value	
Plantar fasciitis	Unvaccinated ^a												
	mRNA vaccine	2.706	1.447-5.057	0.002	1.899	1.305-2.762	0.001	3.105	2.312-4.170	<0.001	2.957	2.493-3.507	<0.001
	Viral vector vaccine	4.261	2.231-8.137	<0.001	2.770	1.872-4.101	<0.001	3.642	2.675-4.958	<0.001	3.486	2.918-4.166	<0.001
	Mixing and matching	3.886	1.819-8.302	<0.001	2.871	1.787-4.611	<0.001	3.975	2.777-5.690	<0.001	3.730	3.023-4.602	<0.001
Rotator cuff syndrome	Unvaccinated ^a												
	mRNA vaccine	3.239	1.873-5.599	<0.001	3.210	2.222-4.637	<0.001	2.817	2.253-3.522	<0.001	2.732	2.420-3.084	<0.001
	Viral vector vaccine	4.459	2.560-7.767	<0.001	4.583	3.158-6.650	<0.001	3.564	2.840-4.473	<0.001	3.290	2.907-3.724	<0.001
	Mixing and matching	5.457	2.890-10.30	<0.001	5.137	3.338-7.903	<0.001	3.958	3.009-5.207	<0.001	3.469	2.978-4.040	<0.001
Adhesive capsulitis	Unvaccinated ^a												
	mRNA vaccine	1.913	1.276-2.868	0.002	2.301	1.710-3.096	<0.001	2.527	2.076-3.075	<0.001	2.550	2.284-2.847	<0.001
	Viral vector vaccine	2.313	1.530-3.496	<0.001	3.012	2.231-4.065	<0.001	2.958	2.422-3.611	<0.001	2.905	2.596-3.251	<0.001
	Mixing and matching	2.197	1.249-3.866	0.006	3.160	2.154-4.636	<0.001	2.894	2.234-3.749	<0.001	2.768	2.390-3.205	<0.001
HIVD	Unvaccinated ^a												
	mRNA vaccine	2.001	1.248-3.211	0.004	1.720	1.239-2.390	0.001	1.813	1.437-2.288	<0.001	1.971	1.730-2.246	<0.001
	Viral vector vaccine	2.138	1.295-3.529	0.003	2.043	1.448-2.880	<0.001	2.200	1.726-2.805	<0.001	2.257	1.969-2.587	<0.001
	Mixing and matching	1.786	0.902-3.540	0.096	2.103	1.342-3.296	0.001	2.327	1.707-3.172	<0.001	2.141	1.789-2.561	<0.001
Spondylosis	Unvaccinated ^a												
	mRNA vaccine	1.242	0.797-1.937	0.339	1.811	1.274-2.575	0.001	1.844	1.453-2.341	<0.001	2.232	1.926-2.586	<0.001
	Viral vector vaccine	1.405	0.889-2.222	0.145	1.829	1.273-2.628	0.001	1.777	1.390-2.273	<0.001	2.226	1.914-2.589	<0.001
	Mixing and matching	1.491	0.757-2.936	0.249	2.036	1.234-3.359	0.005	2.078	1.479-2.918	<0.001	2.345	1.912-2.877	<0.001
Bursitis	Unvaccinated ^a												
	mRNA vaccine	1.199	0.400-3.593	0.746	2.150	0.843-5.478	0.109	1.831	1.039-3.226	0.036	2.097	1.496-2.939	<0.001
	Viral vector vaccine	0.470	0.127-1.739	0.258	1.481	0.545-4.023	0.441	1.372	0.744-2.531	0.311	2.269	1.587-3.243	<0.001
	Mixing and matching	0.654	0.072-5.891	0.705	0.967	0.187-4.999	0.968	1.266	0.510-3.142	0.611	2.700	1.740-4.189	<0.001
Achilles tendinitis	Unvaccinated ^a												

	mRNA vaccine	1.586	0.654-3.843	0.308	1.581	0.866-2.886	0.136	2.500	1.546-4.044	<0.001	2.716	2.082-3.542	<0.001
	Viral vector vaccine	2.194	0.838-5.745	0.109	2.364	1.220-4.581	0.011	2.818	1.663-4.776	<0.001	3.404	2.536-4.570	<0.001
	Mixing and matching	3.572	1.236-10.32	0.019	2.467	1.123-5.419	0.025	3.188	1.734-5.863	<0.001	3.096	2.195-4.368	<0.001
de-Quervain	Unvaccinated ^a												
tenosynovitis	mRNA vaccine	0.781	0.415-1.469	0.443	1.074	0.663-1.738	0.772	1.537	1.070-2.208	0.020	1.404	1.141-1.728	0.001
	Viral vector vaccine	0.817	0.366-1.819	0.620	1.133	0.639-2.009	0.668	1.846	1.221-2.791	0.004	1.627	1.284-2.060	<0.001
	Mixing and matching	0.950	0.341-2.648	0.921	1.183	0.559-2.503	0.661	1.597	0.938-2.718	0.085	1.350	0.982-1.855	0.064

425 OR, Odds ratio; CI, confidence interval; HIVD, herniated intervertebral disc.

426 ^a Unvaccinated group was used for the reference value.

427

428

429

430

431

432


433 **Figures**

434 **Figure 1.** Flowchart of the study populations

435 Inflammatory musculoskeletal disorders include plantar fasciitis, rotator cuff syndrome,

436 adhesive capsulitis, herniated intervertebral disc, spondylosis, bursitis, Achilles tendinitis, and

437 de-Quervain tenosynovitis. NHIS, Korean National Health Insurance Service.




438

439

440 **Figure 2.** Incidence of inflammatory musculoskeletal disorders over time after COVID-19
441 vaccination

442 (A) plantar fasciitis; (B) rotator cuff syndrome; (C) adhesive capsulitis; (D) herniated
443 intervertebral disc; (E) spondylosis; (F) bursitis; (G) Achilles tendinitis; and (H) de-Quervain
444 tenosynovitis. Asterisks indicate that all three vaccinated groups are significantly higher than
445 the unvaccinated group.



446

447

448